Northwest enters manufacturing deals; shares jump


Northwest Biotherapeutics (NWBO) enters into agreements with long-time contract manufacturer Cognate Bioservices for the large-scale expansion of the manufacturing, storage, handling and distribution of Northwest's DCVax-L and DCVax-Direct products.

The company believes that the agreements will give it a head start ahead of Phase III testing of its therapies. Cognate has a "12-year track record of regulatory and operational success with two dozen different cell product trials," Northwest says.

The firm's DCVax products are personalized immune therapies for solid tumor cancers.

Shares are +7.4%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs